← Back to headlines
IN8bio Reports GAAP EPS of -$0.26
IN8bio, a clinical-stage biopharmaceutical company, announced its GAAP EPS of -$0.26, indicating its financial performance for the reported period.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
